Fig. 1 · Structure

Documents & Downloads

GW6471

Cat. No. A12413 CAS 436159-64-7

PPARα antagonist

GW6471 is a PPARα antagonist, shown to completely inhibit GW409544-induced activation of PPARα.

In Stock

Publications for GW6471

1 publication citing this product

  1. Tingting Zhao, .et al. , Aquaculture Research, 2022, 14 February

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GW6471 antagonizes PPARα, but its activity is not confined to that receptor. Competitive binding and cellular reporter assays also demonstrated PPARγ activity. These assay-dependent results support interpreting GW6471 as a dual PPARα/γ antagonist in the tested systems. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

GW6471 Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of GW6471 from 2 published references. In vitro models include cell-free PPAR ligand-binding-domain LanthaScreen TR-FRET assays; HAP1 parental, HAP1 PPARA knockout and HAP1 PPARG knockout human cells.

GW6471 In Vitro Studies

GW6471 reduced MTT metabolic activity in HAP1 cells after 48 h, with similar concentration responses in parental, PPARA-knockout and PPARG-knockout cells. The result limits attribution of this cellular effect to either receptor alone; simultaneous loss of both receptors was not tested. [1]

Competitive binding to PPARα and PPARγ

Biochemical assay · Cell-free PPAR ligand-binding-domain LanthaScreen TR-FRET assays [1]

GW6471 displaced the fluorescent PPAR tracer at both receptors. Binding IC50 values are assay endpoints, not equilibrium binding constants or cellular treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PPARα tracer displacementIC50 95.3 ± 42.0 nM (mean ± SEM; 3 replicates)[1]
PPARγ tracer displacementIC50 39.4 ± 18.2 nM (mean ± SEM; 3 replicates)[1]

Literature-Reported Treatment Conditions

Exposure duration
2 h
Method
Concentration-response competitive binding at room temperature
Vehicle
5% DMSO final
Reported limits
No lot-level analysis reported; final test-concentration range not extracted because stock/intermediate and final assay dilution descriptions are not fully aligned.
Methods and source locations

Compound reported in the paper: GW6471; Compound label in the paper: GW6471

Results concern the specified literature reagent. A12413 stereochemistry, purity and lot activity have not been established by these studies.

Figure 4A–B; Table 1 and footnote a; STAR Methods: Key resources table and Binding affinity assays

PPARα tracer displacement: LanthaScreen TR-FRET; ratio of 520/490 nm emission — Table 1, GW6471 PPARα row and footnote a; Figure 4A; STAR Methods: Binding affinity assays

PPARγ tracer displacement: LanthaScreen TR-FRET; GW9662 comparator — Table 1, GW6471 PPARγ row and footnote a; Figure 4B; STAR Methods: Binding affinity assays

Functional antagonism in PPAR reporter cells

Cell-based study · HeLa-derived HG5LN cells with GAL4RE-luciferase and GAL4–PPARα or GAL4–PPARγ ligand-binding-domain fusions [1]

GW6471 inhibited agonist-driven transcription through both PPARα and PPARγ. Parental HG5LN controls show nonspecific reporter suppression at the highest tested concentrations; the PPARδ reporter showed no antagonism over its tested range.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of GW7647-stimulated PPARα reporter activityIC50 254 ± 96 nM (mean ± SEM; 3 experiments, 4 replicates each)[1]
Inhibition of rosiglitazone-stimulated PPARγ reporter activityIC50 210 ± 64 nM (mean ± SEM; 3 experiments, 4 replicates each)[1]

Literature-Reported Treatment Conditions

Treatment concentration
GW6471 concentration-response series (Figure 4E–F)
Exposure duration
16 h
Method
Living-cell luciferase reporter assay
Co-treatment
PPARα: 10 nM GW7647; PPARγ: 30 nM rosiglitazone
Reported limits
Final solvent percentage not specified in the transcriptional reporter methods.
Methods and source locations

Compound reported in the paper: GW6471; Compound label in the paper: GW6471

Results concern the specified literature reagent. A12413 stereochemistry, purity and lot activity have not been established by these studies.

Figure 4E–F; Table 1 footnote e; Supplement Document S1 Figure S4A–B (PDF p.5); STAR Methods: Transcriptional reporter assays

Inhibition of GW7647-stimulated PPARα reporter activity: HG5LN GAL4–PPARα luciferase assay — Table 1 footnote e and PPARα row; Figure 4E; STAR Methods: Transcriptional reporter assays

Inhibition of rosiglitazone-stimulated PPARγ reporter activity: HG5LN GAL4–PPARγ luciferase assay — Table 1 footnote e and PPARγ row; Figure 4F; STAR Methods: Transcriptional reporter assays

Growth-associated metabolic inhibition persists after single PPAR knockouts

Cell-based study · HAP1 parental, HAP1 PPARA knockout and HAP1 PPARG knockout human cells [1]

The GW6471 concentration-response for MTT reduction was similar in parental and either single-knockout line. This limits attribution of the cellular response to either receptor alone; single knockouts do not test combined PPARA/PPARG loss.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT reduction in parental and single-knockout cellsQualitative concentration-response comparison Similar inhibition across all three cell lines; means ± SD of 3 experiments, 4 replicates per experiment[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.391–100 μM; 0 μM control
Exposure duration
48 h
Method
MTT metabolic activity assay normalized to control
Reported limits
Final vehicle percentage for this assay is not specified in the MTT method. DMSO used to solubilize MTT product is not assumed to be treatment vehicle.
Methods and source locations

Compound reported in the paper: GW6471; Compound label in the paper: GW6471

Results concern the specified literature reagent. A12413 stereochemistry, purity and lot activity have not been established by these studies.

Figure 7A and caption; Supplement Document S1 Figure S8 (PDF p.9); STAR Methods: Cell culture and MTT assay; Limitations of the study

MTT reduction in parental and single-knockout cells: MTT absorbance at 570 nm after 48 h drug exposure — Figure 7A and caption; Results: The in vitro anti-tumor effects of GW6471 are largely off-target; STAR Methods: MTT assay

GW6471 In Vivo Studies

GW6471 (20 mg/kg intraperitoneally every other day for four weeks) reduced Caki-1 renal xenograft growth relative to vehicle in male athymic mice. Combining it with sunitinib did not show synergy. Body weight did not differ among groups; this finding does not establish general safety. [2]

In a separate AB1-Luc mesothelioma model, daily GW6471 at 10 mg/kg, alone or with ABT pretreatment, did not significantly reduce tumor bioluminescence. Tissue invasion remained evident in treated and control mice. This regimen did not establish antitumor efficacy in that model. [1]

No significant tumor-growth benefit in an AB1-Luc mesothelioma model

Animal study · Female BALB/c mice bearing intraperitoneal AB1-Luc mesothelioma; efficacy methods specify BALB/cJAusb, 10–12 weeks [1]

Daily GW6471, with or without ABT pretreatment, did not significantly reduce tumor bioluminescence versus the control groups. Histology showed tissue invasion in treated and control mice. This negative result is specific to this model and regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AB1-Luc tumor bioluminescence over timeBetween-group comparison No significant treatment effect; caption: means ± SD of two replicates, n = 5[1]

Conditions shared by the study groups

Treatment course
Maximum 7 consecutive days, beginning day 4
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GW6471 alone
10 mg/kg
Vehicle-only and ABT + vehicle groupsNo significant reduction in tumor bioluminescence; invasion remained evident.[1]
GW6471 plus ABT
GW6471 10 mg/kg; ABT 50 mg/kg
ABT + vehicle and vehicle-only groupsNo significant reduction in tumor bioluminescence; invasion remained evident.[1]
GW6471 alone
Model: Female BALB/c, AB1-Luc mesothelioma
Route: Intraperitoneal
Frequency: Daily
Vehicle: 40% PEG400 plus 60% of 12.5% Solutol HS-15 in saline
GW6471 plus ABT
Model: Female BALB/c, AB1-Luc mesothelioma
Route: Both intraperitoneal
Frequency: Daily; ABT 2 h before GW6471
Vehicle: GW6471: PEG400/Solutol saline formulation; ABT: 0.9% saline
Methods and source locations

Compound reported in the paper: GW6471; Compound label in the paper: GW6471

Results concern the specified literature reagent. A12413 stereochemistry, purity and lot activity have not been established by these studies.

Figure 6B–E and caption; STAR Methods: Mouse PPARα and PPARγ inhibition assay, Mouse pharmacokinetic studies (cross-referenced dosing), GW6471 formulation preparation

AB1-Luc tumor bioluminescence over time: IVIS average radiance; two-way ANOVA with Dunnett multiple comparisons — Figure 6C–D and caption; Results: Dual inhibition of PPARα/γ does not result in significant anti-mesothelioma activity in vivo

GW6471 alone · Figure 6B–E; STAR Methods: Mouse PPARα and PPARγ inhibition assay and cross-referenced Mouse pharmacokinetic studies

GW6471 plus ABT · Figure 6B–E; STAR Methods: Mouse PPARα and PPARγ inhibition assay, Mouse pharmacokinetic studies and GW6471 formulation preparation

Reduced growth of Caki-1 renal xenografts

Animal study · Male athymic Nu/Nu mice, 8 weeks old, bearing subcutaneous Caki-1 tumors [2]

GW6471 treatment reduced tumor-volume fold change versus vehicle from day 7 through day 28. Sunitinib was an active comparator; the combination did not show synergy. Body-weight comparisons showed no difference, which does not establish general safety or PPARα-specific causality.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume relative to day 1Tumor-growth comparison P < 0.05 versus vehicle from day 7 through day 28; error bars SE[2]
Animal body weight across the treatment courseBetween-group comparison No difference reported; means ± SE[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GW6471 monotherapy
20 mg/kg body weight
Control received 4% DMSO/PBS intraperitoneally and vegetable oil orallyTumor-growth fold change lower than vehicle from day 7 through day 28 (P < 0.05).[2]
GW6471 plus sunitinib
GW6471 20 mg/kg body weight; sunitinib 40 mg/kg body weight
Vehicle controls and each single agentReduced tumor growth versus vehicle; no synergy with sunitinib reported.[2]
GW6471 monotherapy
Model: Male athymic Nu/Nu mice with Caki-1 tumors
Route: Intraperitoneal
Frequency: Every other day
Treatment course: 4 weeks; euthanasia on day 28
Vehicle: 4% DMSO in PBS
Reported limits: Figure 5 and In Vivo Study do not state group size; no n inferred from other assays.
GW6471 plus sunitinib
Model: Male athymic Nu/Nu mice with Caki-1 tumors
Route: GW6471 intraperitoneal; sunitinib oral gavage
Frequency: GW6471 every other day; sunitinib 5 days/week
Treatment course: 4 weeks
Vehicle: GW6471 in 4% DMSO/PBS; sunitinib in vegetable oil
Reported limits: Group size not stated at selected tumor-growth locations; no numerical synergy score reported there.
Methods and source locations

Compound reported in the paper: GW6471; Compound label in the paper: GW6471

Compound-level literature evidence only; no validation of an Adooq lot or stereoisomer composition.

Materials: GW6471 supplier; In Vivo Study and Statistical Analysis; Figures 5–6 and captions; corresponding Results paragraph

Tumor volume relative to day 1: Calipers; volume = length × width²/2; independent-samples t-test described in general statistics — Figure 5 and caption; Results: In Vivo Treatment of a Xenograft Mouse Model With the PPARα Antagonist GW6471 Attenuates RCC Growth

Animal body weight across the treatment course: Weekly weighing and weighing at euthanasia — Figure 6 and caption; Materials and Methods: In Vivo Study

GW6471 monotherapy · In Vivo Study; Figure 5 caption; corresponding Results paragraph

GW6471 plus sunitinib · In Vivo Study; Figure 5 caption; corresponding Results paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 436159-64-7
Applications PPARα antagonist
Formula C35H36F3N3O4
Molecular Weight 619.67
SMILES
CCC(=O)NCC(CC1=CC=C(C=C1)OCCC2=C(OC(=N2)C3=CC=CC=C3)C)NC(=CC(=O)C4=CC=C(C=C4)C(F)(F)F)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (154.92 mM)
Water Insoluble
Ethanol 29 mg/mL (46.8 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GW6471 Research References

  1. [1] Orozco Morales ML, Rinaldi CA, de Jong E, et al. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective iScience (2022). PMID: 34984327 DOI: 10.1016/j.isci.2021.103571 Source material
  2. [2] Abu Aboud O, Donohoe D, Bultman S, et al. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth American journal of physiology. Cell physiology (2015). PMID: 25810260 DOI: 10.1152/ajpcell.00322.2014 Source material

Publications

1 publication citing this product

  1. Tingting Zhao, .et al. , Aquaculture Research, 2022, 14 February

Added to your cart

View Cart Checkout
Loading...